Clinical Trials · NCT04428684
COMPARISON OF A NEW FORMULATION OF GOSERELIN (Pepti 3.6 mg) to Zoladex® 3.6 mg
- Phase
- Phase 1
- Recruitment status
- Completed
- Sponsor
- Peptigroupe Inc.
- Enrollment
- 80
- Start date
- Oct 2018
- Locations
- 5 sites, Ukraine
- Primary endpoint
- Non-inferiority in terms of activity of test drug versus comparator